Advisors Capital Management LLC Has $7.28 Million Stake in Agilent Technologies, Inc. $A

Advisors Capital Management LLC boosted its holdings in Agilent Technologies, Inc. (NYSE:A) by 2.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,270 shares of the medical research company’s stock after purchasing an additional 1,784 shares during the period. Advisors Capital Management LLC’s holdings in Agilent Technologies were worth $7,284,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Agilent Technologies by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company’s stock valued at $3,908,141,000 after buying an additional 240,965 shares during the last quarter. Pictet Asset Management Holding SA increased its stake in Agilent Technologies by 2.5% in the 1st quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company’s stock valued at $624,888,000 after buying an additional 128,131 shares during the last quarter. Generation Investment Management LLP increased its stake in Agilent Technologies by 19.8% in the 1st quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock valued at $582,976,000 after buying an additional 824,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Agilent Technologies by 18.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock valued at $448,748,000 after buying an additional 604,124 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Agilent Technologies by 9.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,231,981 shares of the medical research company’s stock valued at $434,184,000 after buying an additional 283,445 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Barclays reiterated an “equal weight” rating and issued a $125.00 price target on shares of Agilent Technologies in a research note on Friday, August 29th. UBS Group lowered their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a research note on Thursday, May 29th. Wells Fargo & Company lifted their price objective on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, August 28th. Wall Street Zen downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a research report on Thursday, May 29th. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $139.25.

Agilent Technologies Stock Performance

Shares of A opened at $126.88 on Friday. The firm has a 50-day moving average of $119.72 and a 200-day moving average of $116.07. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The company has a market cap of $35.97 billion, a PE ratio of 29.78, a price-to-earnings-growth ratio of 3.86 and a beta of 1.24. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. Agilent Technologies’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of Agilent Technologies stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer owned 37,448 shares of the company’s stock, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.